Skip to content

Novartis AG Price, Chart & Factor Analysis

Free Data & Analytics Access

Latest earnings: April 28, 2026 results vs estimates

Novartis AG · E.NVSN.MX · Mexico
Use symbol E.NVSN.MX in our API & Excel add-in to retrieve this data ↓
2,911.00
(+0.00%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 27.58%

Novartis AG Forecast

Novartis AG short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 27.6% a year, a typical one-standard-deviation range is 2,798–3,024 over a week, 2,679–3,143 over a month and 2,108–3,714 over a year. (Signals as of 5 Nov 2026.)

Novartis AG Price Chart

MacroFinance.ai
Market/MacroIndicatorNowChangeRange
Quantitative
Novartis AG
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Novartis AG
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Novartis AG
Signal
0
ⓘLatest reading of Signal.
Teal = supportive for Novartis AG, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Research on Novartis AG

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Novartis AG Trading Strategies

28 backtested tactical asset allocation strategies hold EEM (emerging markets), the closest tradable exposure to Novartis AG; 2 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

See all 28 strategies holding EEM →

Statistical Distribution of Returns

Plus

How Novartis AG’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Novartis AG behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Novartis AG (Mexico)

Novartis AG is a listed security in Mexico. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

Frequently asked questions

What is Novartis AG?
Novartis AG is a listed security in Mexico. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Novartis AG price?
The latest close is 2,911 (5 Nov 2026), +0.00% on the day. The price at the top of the page refreshes during the trading day.
Is Novartis AG in an uptrend?
As of 5 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Novartis AG?
20-day realised volatility is 27.6% a year (5 Nov 2026), which implies a typical one-standard-deviation move of about 8.0% over a month and 3.9% over a week.
What factors affect Novartis AG?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Novartis AG, grouped as Quantitative Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Novartis AG?
28 backtested tactical asset allocation strategies trade Novartis AG through EEM; 2 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Novartis AG returns analysed?
The Statistical Distribution of Returns section shows the distribution of Novartis AG daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Novartis AG historical data?
In the Free historical data section of this page: the last 10 years of Novartis AG daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Novartis AG historical data (last 10 years)

Browse or instantly download the last 10 years of Novartis AG daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.NVSN.MX&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-192984
2026-11-182984
2026-11-172984
2026-11-132984
2026-11-122984
2026-11-112984
2026-11-103061
2026-11-093042
2026-11-063016.73
2026-11-053009.5
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.